Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BiofarmLTS:0HTH 70 3-Year EBITDA Growth Rate is 11.50% as of Jun. 2026, which is 12% below its 10-year median of 13.10. GuruFocus rates LTS:0HTH with a GF Score™ of 70/100 and a GF Value™ of lei0.14. The stock has 8 warning signs investors should review. Among 807 Drug Manufacturers companies, Biofarm ranks better than 55.39% on this metric.
During the past 12 months, Biofarm's average EBITDA Per Share Growth Rate was -0.90% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 11.50% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 9.60% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 12.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Biofarm was 18.80% per year. The lowest was 0.00% per year. And the median was 13.10% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Biofarm 3-Year EBITDA Growth Rate Related Terms
LTS:0HTH vs ZTS, UTHR, VTRS: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Biofarm's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biofarm 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Biofarm's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Biofarm's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 11.50% mean?
Biofarm (LTS:0HTH) has a 3-Year EBITDA Growth Rate of 11.50% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Biofarm and its competitors. This is 12% below median its historical median of 13.10. According to the industry distribution chart, Biofarm ranks #360 out of 807 companies in the Drug Manufacturers industry, placing it in the top 44.6%.
Is Biofarm's 3-Year EBITDA Growth Rate too high?
Biofarm's current 3-Year EBITDA Growth Rate of 11.50% is 12% below median its 10-year median of 13.10. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.90. Biofarm's value of 11.50% is 29.2% above this industry median. Based on the distribution chart, Biofarm ranks #360 out of 807 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Biofarm has a GF Score™ of 70/100, reflecting its overall financial health beyond just this single metric.
How does Biofarm's 3-Year EBITDA Growth Rate compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Biofarm ranks #360 out of 807 companies for 3-Year EBITDA Growth Rate. This puts Biofarm in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.90. Biofarm's value of 11.50% is 29.2% above this benchmark. While the company's 10-year median is 13.10 vs. the industry median of 8.90, Biofarm has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.90, based on 807 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biofarm's current 3-Year EBITDA Growth Rate of 11.50% is 29.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Biofarm and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biofarm's current 3-Year EBITDA Growth Rate is 11.50%, which is 12% below median its own 10-year median of 13.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biofarm stock overvalued right now?
Biofarm (LTS:0HTH) has a current 3-Year EBITDA Growth Rate of 11.50%. The stock's GF Value™ is lei0.14, compared to a current price of lei0.24 — trading 69.3% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 11.50%, which is 12% below median its 10-year median of 13.10 and 29.2% above the Drug Manufacturers industry median of 8.90. Biofarm's overall GF Score™ is 70/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Biofarm (LTS:0HTH), the current 3-Year EBITDA Growth Rate is 11.50% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biofarm (LTS:0HTH) Overvalued in 2026?
Based on GuruFocus' analysis, Biofarm stock appears to be overvalued.
The current stock price of lei0.24 is trading 69.3% above its estimated GF Value™ of lei0.14.
Key valuation signals for LTS:0HTH:
3-Year EBITDA Growth Rate: 11.50% (12% below median its 10-year median of 13.10)
GF Value™: lei0.14 vs. price of lei0.24 (69.3% above fair value)
Industry Position: 29.2% above the Drug Manufacturers median (#360 of 807)
No single metric tells the full story. See the LTS:0HTH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biofarm SA is a company engaged in production and marketing in the pharmaceutical sector. It is involved in the manufacture and wholesale of over-the-counter drugs, prescription medications, and dietary supplements. The firm's product portfolio includes pharmaceutical preparations for the digestive system, musculoskeletal system, immune stimulation, respiratory system, cold & flu symptoms, and venous circulation improvement, as well as multivitamins, antioxidants, antiseptics, disinfectants, and cosmetics, among others. Some of its brands are Triferment, Colebil, Cavit, Anghirol, Clorocalcin, and Bixtonim. Additionally, the company offers services, such as investment in research, promotion, and packaging.
70GF Score
Get the complete analysis for LTS:0HTH
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0HTH has been successfully added to your 
